Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Braveheart Bio, Inc. (BRVE) news

The news and the share price important stories, numbered as below

Share price since 16 October +4.9%

Stories the last two months, newest first

  1. 1 Results ·

    Braveheart Bio reports third-quarter 2026 results

    Braveheart Bio reported $503.5 million in cash and a runway into 2029, alongside third-quarter net loss of $26.5 million. Its global LIONHEART-HCM Phase 3 trial is enrolling, while TRUEHEART-HCM and NOBLEHEART-HCM trials are planned to begin in the first half of 2027.

    Reported by GlobeNewswire

  2. Other ·

    Braveheart Bio presents 52-week BHB-1893 extension data

    Among 42 patients, exercise capacity and KCCQ scores improved, 79% had a Valsalva LVOT gradient below 30 mmHg at Week 52, and 57% remained on the starting dose. Treatment was generally well tolerated, with no severe or serious on-treatment adverse events. Braveheart plans to start its fixed-dose Phase IIb TRUEHEART-HCM trial in the first half of 2027.

    Reported by 2: GlobeNewswire · MarketBeat

  3. Commentary ·

    Braveheart Bio draws investor attention despite share-price decline

    Braveheart Bio’s experimental hypertrophic cardiomyopathy programs are drawing investor attention despite choppy trading and a 28.22% year-to-date share-price decline. The pre-commercial company reported no revenue and a $98.455 million net loss; forecasts indicate continued losses and no revenue next year. Investors must weigh clinical progress, competition, cash runway and funding needs.

    Reported by Simply Wall St.

More headlines